Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 3 | 7 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375.
-
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Int J Mol Sci. 2023 Apr 27; 24(9).
-
Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10.
-
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119.
-
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. Mol Neurobiol. 2022 Feb; 59(2):1262-1272.
-
Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.
-
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology. 2021; 99(5):310-317.
-
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
-
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
-
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020 10 01; 80(19):4224-4232.